Fig. 6From: Correction to: Inhibition of mTORC1 through ATF4-induced REDD1 and Sestrin2 expression by MetforminLapatinib enhances cell sensitivity to metformin, and knockdown of REDD1 and Sestrin2 decreases cell sensitivity to metformin and lapatinib. (a) H1299 cells were treated with the indicated concentrations of metformin for 24 h. (b) H1299 cells were treated with 10 mM metformin and/or 10 μM lapatinib for 12 h. (c) H1299 cells were treated with 10 mM metformin and/or 10 μM lapatinib for 24 h. (d, f) H1299 cells were transfected with control, ATF4 or REDD1/Sestrin2 siRNA for 12 h followed by treatment with 10 mM metformin and 10 μM lapatinib for 12 h. (e, g) H1299 cells were transfected with control, ATF4, or REDD1/Sestrin2 siRNA for 12 h followed by treatment with 10 mM metformin and 10 μM lapatinib for 24 h. (a. c, e, g) Cell viability was measured by MTT assay. The data are presented as the mean percentage of control ± SD relative to the control (n = 3; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significantly different). (b, d, f) The indicated protein levels were estimated by western blot analysis. Data are representative of three independent experiments. CTL: control, Lapa: Lapatinib, Met: metformin, SESN2: Sestrin2Back to article page